MCP
TBPH icon

Militia Capital Partners’s Theravance Biopharma TBPH Stock Holding History

Militia Capital Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.01M Hold
54,200
– – 0.23% 107
2025
Q3 		$791K Hold
54,200
– – 0.19% 115
2025
Q2 		$598K Buy
+54,200
New +$527K 0.14% 130

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Militia Capital Partners's TBPH Position: Q4 2025 in Review

Militia Capital Partners held its Theravance Biopharma (TBPH) position steady in Q4 2025 at 54,200 shares worth $1.01M. The position accounts for 0.23% of the portfolio, ranked #107.

Militia Capital Partners first reported a position in TBPH in Q2 2025 and has held it in 3 quarters since. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Militia Capital Partners held 54,200 shares of Theravance Biopharma worth $1.01M as of Q4 2025.
  • Militia Capital Partners left its Theravance Biopharma share count unchanged in Q4 2025.
  • Theravance Biopharma made up 0.23% of Militia Capital Partners's portfolio in Q4 2025, its #107 holding.
  • Militia Capital Partners first reported a position in Theravance Biopharma in Q2 2025 and has held it in 3 quarters since.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.